<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272973</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-3692</org_study_id>
    <secondary_id>U1111-1118-0257</secondary_id>
    <secondary_id>2010-019951-23</secondary_id>
    <nct_id>NCT01272973</nct_id>
  </id_info>
  <brief_title>Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate safety,
      tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and
      pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic episodes</measure>
    <time_frame>from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety variables (haematology, biochemistry, and urinalysis)</measure>
    <time_frame>from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of NN9924</measure>
    <time_frame>after dosing on the 68th, 69th and 70th Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve over the dosing interval (0-24 hours)</measure>
    <time_frame>after dosing on the 68th, 69th and 70th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination half-life</measure>
    <time_frame>from last dose (day 70) to follow-up visit 91-105 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.</description>
    <arm_group_label>Oral 1</arm_group_label>
    <arm_group_label>Oral 2</arm_group_label>
    <arm_group_label>Oral 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo (oral) administered once daily for 10 weeks.</description>
    <arm_group_label>Oral 1</arm_group_label>
    <arm_group_label>Oral 2</arm_group_label>
    <arm_group_label>Oral 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.</description>
    <arm_group_label>S.c.</arm_group_label>
    <other_name>NN9924</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects, based on an assessment of medical history, physical examination
             and

          -  BMI between 21 and 30 kg/m2 (21 inclusive)

        Exclusion Criteria:

          -  Male subjects who are sexually active and unwilling to use a highly effective method
             of contraception for both them and their nonpregnant partner

          -  Any clinically significant, abnormal disease history of the following systems:
             cardio-pulmonary, gastrointestinal, hepatic, neurological, renal,genitourinary,
             endocrine or haematological

          -  The receipt of any investigational product within 90 days before screening, or is
             currently enrolled in any other clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

